当前位置： SCI文献检索 > JOURNAL OF CLINICAL PHARMACOLOGY期刊下所有文献 > Comparison of the efficacy and safety of ketorolac and meperidine in the relief of dental pain.

Comparison of the efficacy and safety of ketorolac and meperidine in the relief of dental pain.

Abstract：

:A single-dose, randomized, double-blind study of parallel design was conducted to determine the analgesic efficacy and safety of ketorolac tromethamine in patients who experience moderate or severe pain after the surgical removal of three or more third molars, one of which was a bony-impacted mandibular molar. Meperidine hydrochloride was used as the control analgesic. In this 8-hour study, assessments were made of pain intensity, pain relief, and overall rating of the medication in 145 patients, each of whom had received an intramuscular injection of 10 mg, 30 mg, or 90 mg of ketorolac, or 50 mg or 100 mg of meperidine. The summed pain intensity and total pain relief scores showed that, at 3 and 8 hours, the effectiveness of 30 mg of ketorolac was similar to that of 90 mg ketorolac and that both of these doses were significantly more efficacious than 10-mg ketorolac, 50-mg meperidine, or 100-mg meperidine. Patients who received 30 mg or 90 mg of ketorolac gave the study medication significantly higher ratings overall than did patients who received 50 mg or 100 mg of meperidine. Significantly fewer patients treated with ketorolac reported adverse events in comparison with those treated with meperidine (17% and 59%, respectively), which suggests that it possesses a better therapeutic index than meperidine. Thus, ketorolac appears to represent an important advance in analgesic therapy.

journal_name

J Clin Pharmacol

journal_title

Journal of clinical pharmacology

authors

Fricke JR Jr,Angelocci D,Fox K,McHugh D,Bynum L,Yee JP

doi

10.1002/j.1552-4604.1992.tb03850.x

subject

Has Abstract

pub_date

1992-04-01 00:00:00

pages

376-84

issue

4

eissn

0091-2700

issn

1552-4604

journal_volume

32

pub_type

临床试验,杂志文章,随机对照试验

相关文献

JOURNAL OF CLINICAL PHARMACOLOGY文献大全
  • Atorvastatin does not alter the anticoagulant activity of warfarin.

    abstract：:Twelve patients chronically maintained on warfarin were administered 80 mg atorvastatin for 2 weeks. Mean prothrombin times decreased slightly, but only for the first few days of the two-week treatment period. Thus atorvastatin had no consistent effect on the anticoagulant activity of warfarin and adjustment in warfar...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/j.1552-4604.1997.tb04288.x

    authors： Stern R,Abel R,Gibson GL,Besserer J

    更新日期：1997-11-01 00:00:00

  • Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure-safety relationships.

    abstract：:We report population pharmacokinetic, pharmacodynamic, and pharmacokinetic-safety analyses to support phase II/III dose/regimen selection of alisertib, a selective Aurora A kinase (AAK) inhibitor. Phase I studies in adult cancer patients evaluated dosing on Days 1-7 in 21-day cycles or Days 1-21 in 35-day cycles, with...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/jcph.410

    authors： Venkatakrishnan K,Zhou X,Ecsedy J,Mould DR,Liu H,Danaee H,Fingert H,Kleinfield R,Milton A

    更新日期：2015-03-01 00:00:00

  • Simultaneous first-order and capacity-limited elimination kinetics after oral administration of verapamil.

    abstract：:In this study of the relationship between dose and plasma concentration of verapamil, controlled-release verapamil in doses of 120 mg, 180 mg, 360 mg, and 540 mg were examined. The 48 study subjects received verapamil daily during each of the 4 sequential 5-day dosing segments. Blood samples were collected frequently ...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/j.1552-4604.1996.tb04148.x

    authors： Gupta SK,Hwang S,Atkinson L,Longstreth J

    更新日期：1996-01-01 00:00:00

  • A phase-1, open-label, single-dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment.

    abstract：:The pharmacokinetics (PK) and safety of single-dose buparlisib (30 mg) were assessed in subjects with mild to severe hepatic impairment (n = 6 each) relative to healthy controls (n = 13). Blood samples were collected until 336 hours postdose and evaluated by liquid chromatography tandem mass spectrometry. PK parameter...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/jcph.590

    authors： Csonka D,Hazell K,Waldron E,Lorenzo S,Duval V,Trandafir L,Kobalava ZD

    更新日期：2016-03-01 00:00:00

  • Interaction between sulindac and warfarin: different results in normal subjects and in an unusual patient with a potassium-losing renal tubular defect.

    abstract：:While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin. This difference in individual response with respect to a drug interaction illustrates ...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/j.1552-4604.1979.tb01644.x

    authors： Loftin JP,Vesell ES

    更新日期：1979-11-01 00:00:00

  • Short-term effects of beta blockers atenolol, nadolol, pindolol, and propranolol on lipoprotein metabolism in normolipemic subjects.

    abstract：:The short-term effect of the blockade of the beta-adrenergic receptors on serum lipoproteins and the plasma activities of the enzymes involved in the metabolism of the serum lipoproteins: lipoprotein lipase (LPL), hepatic lipase (HL) and lecithin: cholesterol acyltransferase (LCAT) was evaluated in ten healthy normoli...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/j.1552-4604.1987.tb03052.x

    authors： Harvengt C,Heller FR,Martiat P,Van Nieuwenhuyze Y

    更新日期：1987-07-01 00:00:00

  • Effect of food on pharmacokinetics of an inhaled drug: a case study with a VLA-4 antagonist, HMR1031.

    abstract：:HMR1031 is a potent and specific antagonist of the integrin VLA-4 (alpha4beta1) binding to vascular cell adhesion molecule-1 (VCAM-1) and fibronectin. HMR1031 is an inhaled drug being developed for the treatment of asthma using an Ultrahaler dry-powder inhalation device. A pharmacoscintigraphic study of HMR1031 sugges...

    journal_title：Journal of clinical pharmacology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1177/0091270003258172

    authors： Shah B,Jensen BK,Zhang J,Hunt T,Rohatagi S

    更新日期：2003-12-01 00:00:00

  • A novel CRTH2 antagonist: Single- and multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ACT-453859 in healthy subjects.

    abstract：:The chemoattractant receptor-homologous molecule expressed on T-helper 2 cells (CRTH2) is a G-protein-coupled receptor for prostaglandin D2 , a key mediator in inflammatory disorders. In this randomized, double-blind, placebo-controlled study we investigated the single- and multiple-dose tolerability, pharmacokinetics...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章,随机对照试验

    doi：10.1002/jcph.478

    authors： Géhin M,Strasser DS,Zisowsky J,Farine H,Groenen PM,Dingemanse J,Sidharta PN

    更新日期：2015-07-01 00:00:00

  • Flow cytometric assessment of effects of fluvastatin on low-density lipoprotein receptor activity in stimulated T-lymphocytes from patients with heterozygous familial hypercholesterolemia.

    abstract：:To test the effects of fluvastatin on low-density lipoprotein (LDL) receptor activity in patients with heterozygous familial hypercholesterolemia, the authors measured LDL receptor activity in stimulated T-lymphocytes prepared from 34 patients before and after treatment with 40 mg fluvastatin daily for 12 weeks. Maxim...

    journal_title：Journal of clinical pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1177/00912700022009008

    authors： Raungaard B,Brorholt-Petersen JU,Jensen HK,Faergeman O

    更新日期：2000-04-01 00:00:00

  • Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects.

    abstract：:Atazanavir, a potent protease inhibitor of human immunodeficiency virus (HIV), exhibits pH-dependent solubility. Previous studies have indicated that coadministration with omeprazole 40 mg once daily significantly decreased atazanavir exposure by approximately 75%. Concomitant use of omeprazole and atazanavir is curre...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章,随机对照试验

    doi：10.1177/0091270010367651

    authors： Zhu L,Persson A,Mahnke L,Eley T,Li T,Xu X,Agarwala S,Dragone J,Bertz R

    更新日期：2011-03-01 00:00:00

  • Submission of images to the center for biologics evaluation and research in support of license applications for therapeutic agents.

    abstract：:CBER's philosophy partners with the sponsor's philosophy in the development of electronic dossiers. Based on the experience gained from a number of dossiers, CBER has established a standard management paradigm and imaging platform by which the review of radiographs has been facilitated. ...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1177/009127001773744297

    authors： Fauntleroy M

    更新日期：2001-07-01 00:00:00

  • Pharmacokinetics and rectal bioavailability of hydrocortisone acetate after single and multiple administration in healthy subjects and patients.

    abstract：:The pharmacokinetics and bioavailability of hydrocortisone after rectal administration of a hydrocortisone acetate foam were determined after single and multiple dosing in healthy subjects as well as in patients with inflammatory bowel disease. Endogenous hydrocortisone was suppressed by dexamethasone administration. ...

    journal_title：Journal of clinical pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1177/00912700122010410

    authors： Tromm A,Möllmann H,Barth J,Hochhaus G,Krieg M,Bigalke C,Möllmann A,Derendorf H

    更新日期：2001-05-01 00:00:00

  • Pulmonary function in the elderly: response to theophylline bronchodilation.

    abstract：:This clinical investigation was designed to characterize the pharmacologic response to theophylline in elderly individuals. Incremental theophylline plasma concentrations (0, 5, 10, 15, and 20 mcg/mL), achieved through dose escalation of intravenous aminophylline, were correlated with pulmonary airway responses in ten...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/j.1552-4604.1990.tb03602.x

    authors： Chandler MH,Clifton GD,Burki NK,Hunt BA,Blouin RA

    更新日期：1990-04-01 00:00:00

  • Population Pharmacokinetics of Adjunctive Lacosamide in Pediatric Patients With Epilepsy.

    abstract：:A pediatric population pharmacokinetic model including covariate effects was developed using data from 2 clinical trials in pediatric patients with epilepsy (SP0847 and SP1047). Lacosamide plasma concentration-time data (n = 402) were available from 79 children with body weights ranging from 6 to 76 kg, and a balanced...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/jcph.1340

    authors： Winkler J,Schoemaker R,Stockis A

    更新日期：2019-04-01 00:00:00

  • Different Effects of Atorvastatin on Cardiometabolic Risk Factors in Young Women With and Without Hyperprolactinemia.

    abstract：:Long-term prolactin excess is often accompanied by numerous metabolic complications. No previous study has compared the effect of statin therapy on circulating levels of cardiometabolic risk factors in patients with elevated and normal prolactin levels. The study population consisted of 3 age-, weight-, and lipid-matc...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/jcph.1301

    authors： Krysiak R,Szkróbka W,Okopień B

    更新日期：2019-01-01 00:00:00

  • Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective.

    abstract：:Inhaled glucocorticoids induce therapeutic and adverse systemic effects via the same types of receptors. Analysis of the pharmacokinetic/pharmacodynamic parameters of inhaled glucocorticoids generates a risk-benefit value (RBV). Targeted efficacy with minimal adverse effects helps to quantify an appropriate RBV. High ...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章,评审

    doi：10.1177/0091270003260334

    authors： Rohatagi S,Appajosyula S,Derendorf H,Szefler S,Nave R,Zech K,Banerji D

    更新日期：2004-01-01 00:00:00

  • Grapefruit-drug interactions: can interactions with drugs be avoided?

    abstract：:Grapefruit is rich in flavonoids, which have been demonstrated to have a preventive influence on many chronic diseases, such as cancer and cardiovascular disease. However, since the early 1990s, the potential health benefits of grapefruit have been overshadowed by the possible risk of interactions between drugs and gr...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章,评审

    doi：10.1177/0091270006294277

    authors： Mertens-Talcott SU,Zadezensky I,De Castro WV,Derendorf H,Butterweck V

    更新日期：2006-12-01 00:00:00

  • Fluoxetine bioequivalence study: quantification of fluoxetine and norfluoxetine by liquid chromatography coupled to mass spectrometry.

    abstract：:In this study, the authors assessed the bioequivalence of two fluoxetine tablet formulations in 24 healthy volunteers of both sexes who received a single 20 mg dose of each fluoxetine formulation, and a new sensitive method for the quantification of fluoxetine and norfluoxetine in human plasma was developed. The study...

    journal_title：Journal of clinical pharmacology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1177/00912709922011827

    authors： Moraes MO,Lerner FE,Corso G,Bezerra FA,Moraes ME,De Nucci G

    更新日期：1999-10-01 00:00:00

  • Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects.

    abstract：:In most Wuchereria bancrofti and Brugia malayi infections, the microfilaria are found in the blood in greatest number between 10 p.m. and 2 a.m., indicating that chronotherapy may be beneficial in treating such infections. This study reports the influence of time of administration on the pharmacokinetics of diethylcar...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1177/00912700222011247

    authors： Bolla S,Boinpally RR,Poondru S,Devaraj R,Jasti BR

    更新日期：2002-03-01 00:00:00

  • Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs.

    abstract：:The human cytochrome P450 (CYP) isoforms mediating nortriptyline 10-hydroxylation have been identified using kinetic studies on heterologously expressed human CYPs and chemical inhibition studies on human liver microsomes. Nortriptyline was metabolized to E-10-hydroxynortriptyline by human lymphoblast-expressed CYPs 2...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1177/00912709922008173

    authors： Venkatakrishnan K,von Moltke LL,Greenblatt DJ

    更新日期：1999-06-01 00:00:00

  • Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban.

    abstract：:Argatroban, a direct thrombin inhibitor, is metabolized in vitro by CYP3A4/5 and therefore may be susceptible to clinically relevant CYP3A drug interactions. The effect of erythromycin, a potent CYP3A4/5 inhibitor, on the pharmacokinetics and pharmacodynamics of argatroban was evaluated in 14 healthy male volunteers i...

    journal_title：Journal of clinical pharmacology

    pub_type： 临床试验,杂志文章

    doi：

    authors： Tran JQ,Di Cicco RA,Sheth SB,Tucci M,Peng L,Jorkasky DK,Hursting MJ,Benincosa LJ

    更新日期：1999-05-01 00:00:00

  • Population exposure-response model to support dosing evaluation of ixekizumab in patients with chronic plaque psoriasis.

    abstract：:Ixekizumab (LY2439821), a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody that selectively binds and neutralizes interleukin (IL) 17A has demonstrated efficacy in the treatment of psoriasis. A population pharmacokinetics-pharmacodynamics model was developed using NONMEM 7.2 to describe the temporal re...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1002/jcph.312

    authors： Tham LS,Tang CC,Choi SL,Satterwhite JH,Cameron GS,Banerjee S

    更新日期：2014-10-01 00:00:00

  • Measurement of antipyretic activity of ibuprofen and paracetamol in children.

    abstract：:The antipyretic activity of ibuprofen (Brufen) and paracetamol (Crocin) was compared in 22 children with pyrexia who received either ibuprofen or paracetamol in syrup form. Both axillary and rectal temperatures were recorded prior to drug administration and 1/2, 1, 2, 3, 4, 5, 6, 8, and 12 hours after dosing. Analysis...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/j.1552-4604.1980.tb01685.x

    authors： Sheth UK,Gupta K,Paul T,Pispati PK

    更新日期：1980-11-01 00:00:00

  • Population Pharmacokinetics and Exposure-Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder.

    abstract：:Lemborexant is a novel orexin receptor antagonist approved in the United States and Japan for the treatment of insomnia. This article describes the population pharmacokinetics (PK) of lemborexant and the relationship of its daily steady-state exposure (Cav,ss ) to the probability of most frequent treatment-emergent ad...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/jcph.1683

    authors： Lalovic B,Majid O,Aluri J,Landry I,Moline M,Hussein Z

    更新日期：2020-12-01 00:00:00

  • Pharmacokinetics of valproate after multiple-dose oral and intravenous infusion administration: gastrointestinal-related diurnal variation.

    abstract：:A randomized, crossover study was conducted in healthy male volunteers to assess the diurnal variation in the steady-state pharmacokinetics of valproate after multiple 250-mg oral and intravenous infusion doses after an intravenous 750-mg loading dose. Multiple blood samples were collected throughout each 168-hour stu...

    journal_title：Journal of clinical pharmacology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1002/j.1552-4604.1994.tb02036.x

    authors： Hussein Z,Mukherjee D,Lamm J,Cavanaugh JH,Granneman GR

    更新日期：1994-07-01 00:00:00

  • Pharmacokinetics and safety of solifenacin succinate in healthy young men.

    abstract：:The pharmacokinetic profile of solifenacin succinate (YM905; Vesicare), a new once-daily bladder-selective muscarinic receptor antagonist, was examined in 2 controlled trials of healthy young men. A single-dose study evaluated 5-, 10-, 20-, 40-, 60-, 80-, and 100-mg doses. A multidose study evaluated 5-, 10-, 20-, and...

    journal_title：Journal of clinical pharmacology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1177/0091270004267592

    authors： Smulders RA,Krauwinkel WJ,Swart PJ,Huang M

    更新日期：2004-09-01 00:00:00

  • Exposure-response relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritis.

    abstract：:Relationships between tocilizumab exposure and response were evaluated using data from 4 phase III studies. Increased tocilizumab exposure was associated with improvements in Disease Activity Score using 28 joints (DAS28) and American College of Rheumatology (ACR) criteria and with a decrease in inflammation markers. ...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章,随机对照试验

    doi：10.1177/0091270012437585

    authors： Levi M,Grange S,Frey N

    更新日期：2013-02-01 00:00:00

  • Pharmacokinetics of cibenzoline in patients with renal impairment.

    abstract：:Pharmacokinetic values of cibenzoline, a new, investigational, antiarrhythmic drug, were determined in 13 patients with varying degree of renal impairment, creatinine clearance range between 5 and 53 mL/min. Cibenzoline plasma levels were measured after direct intravenous injection of one single 1 mg/kg dose. The appa...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/j.1552-4604.1985.tb02825.x

    authors： Canal M,Flouvat B,Aubert P,Guedon J,Prinseau J,Baglin A

    更新日期：1985-04-01 00:00:00

  • Interaction between propranolol and propafenone in healthy volunteers.

    abstract：:The effects of propafenone on the pharmacokinetics and pharmacodynamics of propranolol were evaluated in 12 healthy male subjects. Both propafenone and propranolol were each administered alone for one week followed by concomitant administration for an additional week. Blood samples, obtained at steady-state, were anal...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/j.1552-4604.1989.tb03373.x

    authors： Kowey PR,Kirsten EB,Fu CH,Mason WD

    更新日期：1989-06-01 00:00:00

  • New pharmacokinetic methods. II: Determination of the presence or absence of product inhibition in drugs with nonlinear pharmacokinetics.

    abstract：:We show that for drugs metabolized by one enzyme the slope of a plot of serum concentration (C) versus 1/clearance (CL) is linear with a value of 1/Vmax in the presence of substrate saturation and may be linear (rarely) or curved (usually) with a slope always greater than 1/Vmax in the presence of substrate saturation...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/j.1552-4604.1990.tb01859.x

    authors： Browne TR,Szabo GK,Walsh CT,Schumacher GE,Evans JE,Evans BA

    更新日期：1990-07-01 00:00:00